8-K: Onconetix Announces 1-for-10 Reverse Stock Split

Onconetix, Inc. is implementing a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Onconetix, Inc. announced its Board of Directors has approved a 1-for-10 reverse stock split.
• This action is intended to ensure the company remains in compliance with The Nasdaq Stock Market's minimum bid price rule.
• The reverse stock split will become effective on May 21, 2026, at 12:01 a.m. Eastern Time.
• The company's common stock will begin trading on a split-adjusted basis on May 21, 2026, under the symbol ONCO with a new CUSIP number.
• Approximately 11.4 million outstanding shares will be reduced to about 1.14 million shares.
• Fractional shares will not be issued; instead, holders will receive a cash payment based on the closing price on May 20, 2026.
• Adjustments will be made to equity awards, convertible preferred stock, and warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while necessary for compliance, a reverse stock split does not fundamentally alter the company's business prospects or value.

Positives

• The reverse stock split is expected to bring the company into compliance with Nasdaq's minimum bid price requirement, aiding continued listing.
• The ownership percentage of each stockholder will remain unchanged, except for fractional shares.
• The company has secured stockholder approval for reverse stock splits within a specified range.

Negatives

• The reverse stock split is a consequence of the company's stock price falling below Nasdaq's minimum bid price requirement.
• Holders of fractional shares will receive cash payments, which may not be desirable for all investors.

Risks

• Failure to maintain compliance with Nasdaq's continued listing requirements could lead to delisting.
• There are significant risks in the development, regulatory approval, and commercialization of biotechnology products.
• Market and other conditions could impact the company's ability to remain trading on the Nasdaq Stock Market.

Future Outlook

The reverse stock split is intended to ensure compliance with Nasdaq's minimum bid price requirement, thereby facilitating continued listing on the Nasdaq Stock Market. The company anticipates the reverse stock split will become effective on May 21, 2026.

Management Comments

• The reverse stock split is primarily intended to bring the Company into compliance with The Nasdaq Stock Market, LLCs rule on minimum bid price requirements.
• The reverse stock split is intended to enable the Company to maintain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common tactic for companies facing delisting due to low share prices, particularly in the biotechnology sector where stock volatility can be high. This move aims to maintain market access on major exchanges like Nasdaq.

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares reduced by a factor of 10, but their ownership percentage will remain the same, except for fractional shares.
• Holders of fractional shares will receive cash, potentially impacting their investment value.
• The continued listing on Nasdaq is positive for all stakeholders, ensuring market liquidity and access.

Next Steps

• File an amendment to the Charter with the Secretary of State of the State of Delaware on May 20, 2026.
• The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 21, 2026.
• The company's Common Stock will begin trading on a split-adjusted basis when the Nasdaq Stock Market opens on May 21, 2026.

Key Dates

Recommendation

The reverse stock split is a procedural move to maintain Nasdaq listing and does not inherently change the company's underlying business performance or prospects. Investors should continue to evaluate the company based on its biotechnology pipeline and commercialization efforts.

Keywords

reverse stock split, Onconetix, Nasdaq compliance, biotechnology, stock adjustment, common stock, SEC filing, 8-K